Sutro Biopharma
STRO
60 hedge funds and large institutions have $122M invested in Sutro Biopharma in 2020 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 29 increasing their positions, 15 reducing their positions, and 5 closing their positions.
93% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 15
0.13% more ownership
Funds ownership: 5.03% → 5.16% (+0.13%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less capital invested
Capital invested by funds: $128M → $122M (-$6.16M)
6% less funds holding
Funds holding: 64 → 60 (-4)
60% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Adage Capital Partners
Boston,
Massachusetts
|
+$4.2M |
| 2 |
Barclays
London,
United Kingdom
|
+$2.22M |
| 3 |
Janus Henderson Group
London,
United Kingdom
|
+$1.49M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$1.37M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
+$1.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VM
VV Manager
Boston,
Massachusetts
|
-$5.58M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$1.89M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$655K |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$629K |
| 5 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$424K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Deutsche Bank
Frankfurt Am Main Ge,
Germany
| $34K | -$43.9K | -418 | -55% |
|
52
Citigroup
New York
| $31K | +$9.35K | +89 | +41% |
|
|
MAM
53
Meeder Asset Management
Dublin,
Ohio
| $23K | +$20.5K | +195 | +672% |
|
|
SO
54
STRS Ohio
Columbus,
Ohio
| $17K | – | – | – |
|
55
Legal & General Group
London,
United Kingdom
| $14K | -$5.25K | -50 | -26% |
|
56
Royal Bank of Canada
Toronto,
Ontario, Canada
| $12K | +$1.79K | +17 | +17% |
|
57
Morgan Stanley
New York
| $9K | -$176K | -1,676 | -95% |
|
|
AIP
58
Ameritas Investment Partners
Lincoln,
Nebraska
| $5K | – | – | – |
|
|
PCM
59
Prelude Capital Management
New York
| $3K | – | – | – |
|
60
Osaic Holdings
Scottsdale,
Arizona
| $2K | +$2.1K | +20 | New |
|
|
BCM
61
Bridgeway Capital Management
Houston,
Texas
| – | -$629K | -5,720 | Closed |
|
|
ECM
62
Endurant Capital Management
San Mateo,
California
| – | -$359K | -3,267 | Closed |
|
63
Renaissance Technologies
New York
| – | -$113K | -1,030 | Closed |
|
|
TI
64
Trexquant Investment
Stamford,
Connecticut
| – | -$112K | -1,022 | Closed |
|
65
Bank of Montreal
Toronto,
Ontario, Canada
| – | -$23K | -209 | Closed |
|
STRO Hedge Fund Activity: Q1 2020 in Review
60 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Sutro Biopharma (STRO) for Q1 2020, worth a combined $122M — down 4.8% from $128M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of STRO and 2 opened new positions — a net loss of 3 holders — while 15 trimmed existing stakes and 29 added.
The largest buyer was Adage Capital Partners, adding an estimated $4.2M. The largest seller was VV Manager, cutting an estimated $5.58M.
- 60 institutional investors held Sutro Biopharma (STRO) as of Q1 2020, down from 64 in Q4 2019.
- Funds reported $122M of Sutro Biopharma stock for Q1 2020, down 4.8% quarter-over-quarter.
- 2 funds opened new Sutro Biopharma positions in Q1 2020 and 5 closed out, a net change of -3 holders.
- The largest Sutro Biopharma buyer in Q1 2020 was Adage Capital Partners, an estimated $4.2M added.
- The largest Sutro Biopharma seller in Q1 2020 was VV Manager, an estimated $5.58M sold.
Based on aggregated 13F filings for Q1 2020.